This study is testing a new drug called suvecaltamide to help adults with Parkinson's disease (a brain condition that affects movement) who have moderate to severe tremor (shaking). Participants will be randomly assigned to receive either suvecaltamide or a placebo (a pill that looks like the drug but doesn't contain it). The study lasts up to 23 weeks, including a Screening Period (up to 4 weeks), a 5-week Dose Titration and Optimization Period, a 12-week Maintenance Period, and a 2-week Safety Follow-up Period. To join, individuals must have Parkinson's with tremors that disrupt daily activities and have been on stable medication for at least 6 weeks. Pregnant women and those with certain medical conditions cannot participate.

• Study Duration: Up to 23 weeks, with 17 weeks of treatment.
• Visits: Multiple visits required over the study period.
• Eligibility: Must have Parkinson's with significant tremor.

Participants will not receive treatment if they have certain health issues or if their tremor only occurs during specific times.